Off-Label Marketing Suit Costs Novartis $72M
Two Novartis AG units have agreed to pay $72.5 million to settle a whistleblower suit alleging they knowingly marketed the cystic fibrosis drug Tobi for uses not approved by the U.S....To view the full article, register now.
Already a subscriber? Click here to view full article